{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T17:57:33Z","timestamp":1792173453339,"version":"4.4.0"},"reference-count":278,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ajog.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Obstetrics and Gynecology"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1016\/j.ajog.2017.06.003","type":"journal-article","created":{"date-parts":[[2017,6,12]],"date-time":"2017-06-12T03:01:15Z","timestamp":1497236475000},"page":"282-302","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":231,"title":["Metformin, the aspirin of the 21st century: its\u00a0role in gestational diabetes mellitus, prevention of preeclampsia and cancer, and\u00a0the promotion of longevity"],"prefix":"10.1016","volume":"217","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4448-5121","authenticated-orcid":false,"given":"Roberto","family":"Romero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Offer","family":"Erez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maik","family":"H\u00fcttemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eli","family":"Maymon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bogdan","family":"Panaitescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agustin","family":"Conde-Agudelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Percy","family":"Pacora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo Hyun","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence I.","family":"Grossman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajog.2017.06.003_bib1","doi-asserted-by":"crossref","first-page":"e8758","DOI":"10.1371\/journal.pone.0008758","article-title":"Metformin induces a dietary restriction-like state and the oxidative stress response to extend C. elegans Healthspan via AMPK, LKB1, and SKN-1","volume":"5","author":"Onken","year":"2010","journal-title":"PloS One"},{"key":"10.1016\/j.ajog.2017.06.003_bib2","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.cell.2013.02.035","article-title":"Metformin retards aging in C elegans by altering microbial folate and methionine metabolism","volume":"153","author":"Cabreiro","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.ajog.2017.06.003_bib3","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1038\/ncomms3192","article-title":"Metformin improves healthspan and lifespan in mice","volume":"4","author":"Martin-Montalvo","year":"2013","journal-title":"Nat Commun"},{"key":"10.1016\/j.ajog.2017.06.003_bib4","doi-asserted-by":"crossref","first-page":"E2501","DOI":"10.1073\/pnas.1321776111","article-title":"Metformin promotes lifespan through mitohormesis via the peroxiredoxin PRDX-2","volume":"111","author":"De Haes","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ajog.2017.06.003_bib5","unstructured":"Crandall J. Metformin in Longevity Study (MILES). Clinical Trial.gov., 2015. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02432287."},{"key":"10.1016\/j.ajog.2017.06.003_bib6","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/j.cmet.2016.05.011","article-title":"Metformin as a tool to target aging","volume":"23","author":"Barzilai","year":"2016","journal-title":"Cell Metab"},{"key":"10.1016\/j.ajog.2017.06.003_bib7","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1093\/aje\/kwu124","article-title":"Reduced risk of lung cancer with metformin therapy in diabetic patients: a systematic review and meta-analysis","volume":"180","author":"Zhang","year":"2014","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.ajog.2017.06.003_bib8","doi-asserted-by":"crossref","first-page":"e71583","DOI":"10.1371\/journal.pone.0071583","article-title":"Metformin therapy and risk of cancer in patients with type 2 diabetes: systematic review","volume":"8","author":"Franciosi","year":"2013","journal-title":"PloS One"},{"key":"10.1016\/j.ajog.2017.06.003_bib9","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.diabres.2014.04.007","article-title":"Metformin is associated with reduced risk of pancreatic cancer in patients with type 2 diabetes mellitus: a systematic review and meta-analysis","volume":"106","author":"Wang","year":"2014","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.ajog.2017.06.003_bib10","doi-asserted-by":"crossref","first-page":"10147","DOI":"10.1038\/srep10147","article-title":"Pharmacologic therapy of diabetes and overall cancer risk and mortality: a meta-analysis of 265 studies","volume":"5","author":"Wu","year":"2015","journal-title":"Scientific Rep"},{"key":"10.1016\/j.ajog.2017.06.003_bib11","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.atherosclerosis.2015.07.017","article-title":"Metformin modulates human leukocyte\/endothelial cell interactions and proinflammatory cytokines in polycystic ovary syndrome patients","volume":"242","author":"Victor","year":"2015","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ajog.2017.06.003_bib12","doi-asserted-by":"crossref","first-page":"E120","DOI":"10.25011\/cim.v39i4.27091","article-title":"Effect of metformin treatment during pregnancy on women with PCOS: a systematic review and meta-analysis","volume":"39","author":"Tan","year":"2016","journal-title":"Clin Invest Med"},{"key":"10.1016\/j.ajog.2017.06.003_bib13","doi-asserted-by":"crossref","first-page":"833","DOI":"10.3109\/09513590.2015.1041906","article-title":"Efficacy of metformin on pregnancy complications in women with polycystic ovary syndrome: a meta-analysis","volume":"31","author":"Feng","year":"2015","journal-title":"Gynecol Endocrinol"},{"key":"10.1016\/j.ajog.2017.06.003_bib14","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/j.1742-7843.2005.pto_96602.x","article-title":"Is metformin therapy for polycystic ovary syndrome safe during pregnancy?","volume":"96","author":"Brock","year":"2005","journal-title":"Basic Clin Pharmacol toxicol"},{"key":"10.1016\/j.ajog.2017.06.003_bib15","doi-asserted-by":"crossref","first-page":"191","DOI":"10.7326\/M16-1901","article-title":"Clinical outcomes of metformin use in populations with chronic kidney disease, congestive heart failure, or chronic liver disease: a systematic review","volume":"166","author":"Crowley","year":"2017","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ajog.2017.06.003_bib16","doi-asserted-by":"crossref","first-page":"8005","DOI":"10.4049\/jimmunol.0803563","article-title":"Metformin attenuated the autoimmune disease of the central nervous system in animal models of multiple sclerosis","volume":"182","author":"Nath","year":"2009","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.ajog.2017.06.003_bib17","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1001\/jamaneurol.2015.4807","article-title":"Immunologic effects of metformin and pioglitazone treatment on metabolic syndrome and multiple sclerosis","volume":"73","author":"Negrotto","year":"2016","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.ajog.2017.06.003_bib18","doi-asserted-by":"crossref","first-page":"981","DOI":"10.2337\/db10-0655","article-title":"Tubular injury in a rat model of type 2 diabetes is prevented by metformin: a possible role of HIF-1alpha expression and oxygen metabolism","volume":"60","author":"Takiyama","year":"2011","journal-title":"Diabetes"},{"key":"10.1016\/j.ajog.2017.06.003_bib19","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.4254\/wjh.v7.i12.1652","article-title":"Systematic review: preventive and therapeutic applications of metformin in liver disease","volume":"7","author":"Bhat","year":"2015","journal-title":"World J Hepatol"},{"key":"10.1016\/j.ajog.2017.06.003_bib20","doi-asserted-by":"crossref","first-page":"356.e1","DOI":"10.1016\/j.ajog.2015.12.019","article-title":"Metformin as a prevention and treatment for preeclampsia: effects on soluble fms-like tyrosine kinase 1 and soluble endoglin secretion and endothelial dysfunction","volume":"214","author":"Brownfoot","year":"2016","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2017.06.003_bib21","first-page":"1122","article-title":"Hypertension in Pregnancy. Report of the American College of Obstetricians and Gynecologists' Task Force on Hypertension in Pregnancy","volume":"122","year":"2013","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ajog.2017.06.003_bib22","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1172\/JCI14178","article-title":"The blooming of the French lilac","volume":"108","author":"Witters","year":"2001","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.ajog.2017.06.003_bib23","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1056\/NEJM199602293340906","article-title":"Metformin","volume":"334","author":"Bailey","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajog.2017.06.003_bib24","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/pdi.606","article-title":"Metformin: its botanical background","volume":"21","author":"Bailey","year":"2004","journal-title":"Pract Diabetes Int"},{"key":"10.1016\/j.ajog.2017.06.003_bib25","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0021-9258(18)86579-6","article-title":"Studies in the metabolic changes induced by administration of guanidine bases","volume":"33","author":"Watanabe","year":"1918","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.ajog.2017.06.003_bib26","series-title":"Oral hypoglycaemic agents: pharmacology and therapeutics","first-page":"193","article-title":"Pharmacology and mode of action of the hypoglycaemic guanidine derivatives","author":"Sterne","year":"1969"},{"key":"10.1016\/j.ajog.2017.06.003_bib27","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1007\/BF01862957","article-title":"Pharmacology of galegin","volume":"125","author":"Muller","year":"1927","journal-title":"Arch Expll Path Pharm"},{"key":"10.1016\/j.ajog.2017.06.003_bib28","article-title":"[Sur les propietes hypoglycemiantes du sulfate de galegine.]","volume":"8","author":"Simonnet","year":"1927","journal-title":"Bull Soc Chim Biol Paris"},{"key":"10.1016\/j.ajog.2017.06.003_bib29","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/BF01263443","article-title":"Biguanides","volume":"14","author":"Nattrass","year":"1978","journal-title":"Diabetologia"},{"key":"10.1016\/j.ajog.2017.06.003_bib30","first-page":"85","article-title":"[Recherches sur le role du pancreas dans l\u2019assimilation nutritive.]","volume":"17","author":"Paulesco","year":"1921","journal-title":"Arch Int Physiol"},{"key":"10.1016\/j.ajog.2017.06.003_bib31","first-page":"141","article-title":"Pancreatic extracts in the treatment of diabetes mellitus","volume":"12","author":"Banting","year":"1922","journal-title":"Can Med Assoc J"},{"key":"10.1016\/j.ajog.2017.06.003_bib32","first-page":"625","article-title":"[Treatment of diabetes mellitus with N,N-dimethylguanylguanidine (LA. 6023, glucophage)]","volume":"14","author":"Sterne","year":"1959","journal-title":"Therapie"},{"key":"10.1016\/j.ajog.2017.06.003_bib33","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1001\/jama.1963.03700140099014","article-title":"Lactic acidosis and phenformin hydrochloride","volume":"184","author":"Bernier","year":"1963","journal-title":"JAMA"},{"key":"10.1016\/j.ajog.2017.06.003_bib34","doi-asserted-by":"crossref","first-page":"878","DOI":"10.7326\/0003-4819-59-6-878","article-title":"Lactate acidosis associated with phenformin therapy and localized tissue hypoxia: report of a case treated by hemodialysis","volume":"59","author":"Ewy","year":"1963","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ajog.2017.06.003_bib35","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1001\/jama.1963.03700140093013","article-title":"Irreversible lactic acidosis associated with phenformine therapy: report of three cases","volume":"184","author":"Tranquada","year":"1963","journal-title":"JAMA"},{"key":"10.1016\/j.ajog.2017.06.003_bib36","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1056\/NEJM196610202751606","article-title":"Phenformin, hypoglycemia and lactic acidosis: report of attempted suicide","volume":"275","author":"Davidson","year":"1966","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ajog.2017.06.003_bib37","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1136\/bmj.4.5573.216","article-title":"Fatal lactic acidosis after an overdose of phenformin","volume":"4","author":"Proctor","year":"1967","journal-title":"Br Med J"},{"key":"10.1016\/j.ajog.2017.06.003_bib38","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1136\/bmj.3.5721.506","article-title":"Hypothermia, abdominal pain, and lactic acidosis in phenformin-treated diabetic","volume":"3","author":"Shirriffs","year":"1970","journal-title":"Br Med J"},{"key":"10.1016\/j.ajog.2017.06.003_bib39","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2337\/dc08-9025","article-title":"Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes","volume":"32","author":"Nathan","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ajog.2017.06.003_bib40","doi-asserted-by":"crossref","first-page":"140","DOI":"10.2337\/dc14-2441","article-title":"Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes","volume":"38","author":"Inzucchi","year":"2015","journal-title":"Diabetes Care"},{"issue":"suppl1","key":"10.1016\/j.ajog.2017.06.003_bib41","first-page":"S36","article-title":"4. Prevention or delay of type 2 diabetes","volume":"39","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ajog.2017.06.003_bib42","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/S2213-8587(15)00291-0","article-title":"Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up: the Diabetes Prevention Program Outcomes Study","volume":"3","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.ajog.2017.06.003_bib43","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJMoa012512","article-title":"Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin","volume":"346","author":"Knowler","year":"2002","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ajog.2017.06.003_bib44","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1007\/s00125-006-0141-7","article-title":"Effects of metformin and thiazolidinediones on suppression of hepatic glucose production and stimulation of glucose uptake in type 2 diabetes: a systematic review","volume":"49","author":"Natali","year":"2006","journal-title":"Diabetologia"},{"key":"10.1016\/j.ajog.2017.06.003_bib45","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.cmet.2014.09.018","article-title":"Metformin: from mechanisms of action to therapies","volume":"20","author":"Foretz","year":"2014","journal-title":"Cell Metab"},{"key":"10.1016\/j.ajog.2017.06.003_bib46","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1042\/CS20110386","article-title":"Cellular and molecular mechanisms of metformin: an overview","volume":"122","author":"Viollet","year":"2012","journal-title":"Clin Sci"},{"key":"10.1016\/j.ajog.2017.06.003_bib47","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/BF01221950","article-title":"Metformin in management of pregnant insulin-independent diabetics","volume":"16","author":"Coetzee","year":"1979","journal-title":"Diabetologia"},{"key":"10.1016\/j.ajog.2017.06.003_bib48","first-page":"467","article-title":"Diabetes newly diagnosed during pregnancy: a 4-year study at Groote Schuur Hospital","volume":"56","author":"Coetzee","year":"1979","journal-title":"S\u00a0Afr Med J"},{"key":"10.1016\/j.ajog.2017.06.003_bib49","first-page":"1113","article-title":"Side-effects of metformin","volume":"56","author":"Jackson","year":"1979","journal-title":"S\u00a0Afr Med J"},{"key":"10.1016\/j.ajog.2017.06.003_bib50","first-page":"795","article-title":"Pregnancy in established non-insulin-dependent diabetics: a five-and-a-half year study at Groote Schuur Hospital","volume":"58","author":"Coetzee","year":"1980","journal-title":"S\u00a0Afr Med J"},{"key":"10.1016\/j.ajog.2017.06.003_bib51","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0002-9378(97)70541-6","article-title":"Human placental glucose uptake and transport are not altered by the oral antihyperglycemic agent metformin","volume":"176","author":"Elliott","year":"1997","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2017.06.003_bib52","doi-asserted-by":"crossref","first-page":"462","DOI":"10.5694\/j.1326-5377.2004.tb06024.x","article-title":"Metformin therapy and diabetes in pregnancy","volume":"180","author":"Simmons","year":"2004","journal-title":"Med J Aust"},{"key":"10.1016\/j.ajog.2017.06.003_bib53","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1093\/humrep\/deh347","article-title":"Metformin reduces pregnancy complications without affecting androgen levels in pregnant polycystic ovary syndrome women: results of a randomized study","volume":"19","author":"Vanky","year":"2004","journal-title":"Hum Reprod"},{"issue":"suppl2","key":"10.1016\/j.ajog.2017.06.003_bib54","doi-asserted-by":"crossref","first-page":"S206","DOI":"10.2337\/dc07-s217","article-title":"Pharmacological management of gestational diabetes: an overview","volume":"30","author":"Coustan","year":"2007","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ajog.2017.06.003_bib55","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1056\/NEJMe0802623","article-title":"Gestational diabetes: setting limits, exploring treatments","volume":"358","author":"Ecker","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ajog.2017.06.003_bib56","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1056\/NEJMoa0707193","article-title":"Metformin versus insulin for the treatment of gestational diabetes","volume":"358","author":"Rowan","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ajog.2017.06.003_bib57","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s11892-009-0044-3","article-title":"The use of oral antidiabetic medications in gestational diabetes mellitus","volume":"9","author":"Paglia","year":"2009","journal-title":"Curr Diabetes Rep"},{"key":"10.1016\/j.ajog.2017.06.003_bib58","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1517\/14656566.3.11.1557","article-title":"The contentious nature of gestational diabetes: diet, insulin, glyburide and metformin","volume":"3","author":"Glueck","year":"2002","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.ajog.2017.06.003_bib59","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/S0015-0282(01)03202-2","article-title":"Metformin therapy throughout pregnancy reduces the development of gestational diabetes in women with polycystic ovary syndrome","volume":"77","author":"Glueck","year":"2002","journal-title":"Fertil Steril"},{"key":"10.1016\/j.ajog.2017.06.003_bib60","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s11892-003-0022-0","article-title":"Metformin and gestational diabetes","volume":"3","author":"Glueck","year":"2003","journal-title":"Current Diabetes Rep"},{"key":"10.1016\/j.ajog.2017.06.003_bib61","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1080\/14767050600863376","article-title":"Insulins and oral hypoglycemic agents in pregnancy","volume":"19","author":"Homko","year":"2006","journal-title":"J\u00a0Matern Fetal Neonatal Med"},{"key":"10.1016\/j.ajog.2017.06.003_bib62","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1159\/000094449","article-title":"Diet and medical therapy in the optimal management of gestational diabetes mellitus","volume":"11","author":"Metzger","year":"2006","journal-title":"Nestle Nutr Workshop Ser Clin Perform programme"},{"key":"10.1016\/j.ajog.2017.06.003_bib63","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1124\/dmd.109.031245","article-title":"Pharmacokinetics of metformin during pregnancy","volume":"38","author":"Eyal","year":"2010","journal-title":"Drug Metabo Dispos"},{"key":"10.1016\/j.ajog.2017.06.003_bib64","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s11892-011-0249-0","article-title":"Management of diabetes in pregnancy","volume":"12","author":"Ballas","year":"2012","journal-title":"Current Diabetes Rep"},{"key":"10.1016\/j.ajog.2017.06.003_bib65","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s40748-015-0021-6","article-title":"Oral hypoglycemic agents: do the ends justify the means? Matern Health","volume":"1","author":"Langer","year":"2015","journal-title":"Neonatol Perinatol"},{"key":"10.1016\/j.ajog.2017.06.003_bib66","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/S2213-8587(16)30278-9","article-title":"Clinical management of pregnancy in the obese mother: before conception, during pregnancy, and post partum","volume":"4","author":"Ma","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.ajog.2017.06.003_bib67","doi-asserted-by":"crossref","first-page":"284","DOI":"10.4103\/2230-8210.85580","article-title":"Gestational diabetes mellitus: non-insulin management","volume":"15","author":"Magon","year":"2011","journal-title":"Indian J Endocrinol Metab"},{"key":"10.1016\/j.ajog.2017.06.003_bib68","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.4239\/wjd.v6.i8.1065","article-title":"Gestational diabetes: a clinical update","volume":"6","author":"Kampmann","year":"2015","journal-title":"World J Diabetes"},{"key":"10.1016\/j.ajog.2017.06.003_bib69","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1056\/NEJM199508313330902","article-title":"Efficacy of metformin in patients with noninsulin-dependent diabetes mellitus. The Multicenter Metformin Study Group","volume":"333","author":"DeFronzo","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajog.2017.06.003_bib70","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/S0140-6736(98)07037-8","article-title":"Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group","volume":"352","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.ajog.2017.06.003_bib71","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1111\/j.1471-0528.2010.02763.x","article-title":"Metformin should be considered in the treatment of gestational diabetes: a prospective randomised study","volume":"118","author":"Ijas","year":"2011","journal-title":"BJOG"},{"key":"10.1016\/j.ajog.2017.06.003_bib72","first-page":"1011","article-title":"Metformin and insulin in the management of gestational diabetes mellitus: preliminary results of a comparison","volume":"52","author":"Moore","year":"2007","journal-title":"J\u00a0Reprod Med"},{"key":"10.1016\/j.ajog.2017.06.003_bib73","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.diabres.2012.09.031","article-title":"Metformin compared with insulin in the management of gestational diabetes mellitus: a randomized clinical trial","volume":"98","author":"Niromanesh","year":"2012","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.ajog.2017.06.003_bib74","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/dom.12017","article-title":"Metformin vs insulin in gestational diabetes: a randomized study characterizing metformin patients needing additional insulin","volume":"15","author":"Tertti","year":"2013","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.ajog.2017.06.003_bib75","doi-asserted-by":"crossref","first-page":"e64585","DOI":"10.1371\/journal.pone.0064585","article-title":"Metformin vs insulin in the management of gestational diabetes: a meta-analysis","volume":"8","author":"Gui","year":"2013","journal-title":"PloS One"},{"key":"10.1016\/j.ajog.2017.06.003_bib76","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1080\/14767058.2016.1228061","article-title":"Metformin: a potentially effective drug for gestational diabetes mellitus: a systematic review and meta-analysis","volume":"30","author":"Feng","year":"2017","journal-title":"J Matern Fetal Neonatal Med"},{"key":"10.1016\/j.ajog.2017.06.003_bib77","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/dme.13150","article-title":"Short- and long-term outcomes of metformin compared with insulin alone in pregnancy: a systematic review and meta-analysis","volume":"34","author":"Butalia","year":"2017","journal-title":"Diabetic Med"},{"key":"10.1016\/j.ajog.2017.06.003_bib78","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1055\/s-0032-1326994","article-title":"Metformin compared with insulin in the treatment of pregnant women with overt diabetes: a randomized controlled trial","volume":"30","author":"Hickman","year":"2013","journal-title":"Am J Perinatol"},{"key":"10.1016\/j.ajog.2017.06.003_bib79","doi-asserted-by":"crossref","first-page":"34.e1","DOI":"10.1016\/j.ajog.2013.03.022","article-title":"Randomized trial of metformin vs insulin in the management of gestational diabetes","volume":"209","author":"Spaulonci","year":"2013","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2017.06.003_bib80","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1007\/s00404-013-3090-7","article-title":"The role of adding metformin in insulin-resistant diabetic pregnant women: a randomized controlled trial","volume":"289","author":"Ibrahim","year":"2014","journal-title":"Arch Gynecol Obstet"},{"key":"10.1016\/j.ajog.2017.06.003_bib81","first-page":"970","article-title":"Neonatal outcomes in women with gestational diabetes mellitus treated with metformin in compare with insulin: a randomized clinical trial","volume":"19","author":"Ruholamin","year":"2014","journal-title":"J\u00a0res med sci"},{"key":"10.1016\/j.ajog.2017.06.003_bib82","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.diabres.2014.10.001","article-title":"Metformin versus insulin treatment in gestational diabetes in pregnancy in a developing country: a randomized control trial","volume":"107","author":"Ainuddin","year":"2015","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.ajog.2017.06.003_bib83","first-page":"163","article-title":"A\u00a0pilot randomized, controlled trial of metformin versus insulin in women with type 2 diabetes mellitus during pregnancy","volume":"30","author":"Refuerzo","year":"2015","journal-title":"American J Perinatol"},{"key":"10.1016\/j.ajog.2017.06.003_bib84","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/S0002-9378(88)80169-8","article-title":"Preeclampsia is associated with a serum factor cytotoxic to human endothelial cells","volume":"159","author":"Rodgers","year":"1988","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2017.06.003_bib85","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/0002-9378(89)90665-0","article-title":"Preeclampsia: an endothelial cell disorder","volume":"161","author":"Roberts","year":"1989","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2017.06.003_bib86","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/j.1538-7836.2008.03259.x","article-title":"Vascular biology of preeclampsia","volume":"7","author":"Myatt","year":"2009","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.ajog.2017.06.003_bib87","first-page":"79","article-title":"Oxidative stress causes vascular dysfunction in the placenta","volume":"9","author":"Myatt","year":"2000","journal-title":"J\u00a0Matern Fetal Med"},{"key":"10.1016\/j.ajog.2017.06.003_bib88","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1053\/ob.1996.v175.a74252","article-title":"Decreased transferrin and increased transferrin saturation in sera of women with preeclampsia: implications for oxidative stress","volume":"175","author":"Hubel","year":"1996","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2017.06.003_bib89","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/S0002-9378(96)70410-6","article-title":"Hyperuricemia and xanthine oxidase in preeclampsia, revisited","volume":"174","author":"Many","year":"1996","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2017.06.003_bib90","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.jsgi.2004.03.003","article-title":"Placental oxidative stress: from miscarriage to preeclampsia","volume":"11","author":"Burton","year":"2004","journal-title":"J\u00a0Soc Gynecol Investig"},{"issue":"supplA","key":"10.1016\/j.ajog.2017.06.003_bib91","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1016\/j.placenta.2008.11.003","article-title":"Placental endoplasmic reticulum stress and oxidative stress in the pathophysiology of unexplained intrauterine growth restriction and early onset preeclampsia","volume":"30","author":"Burton","year":"2009","journal-title":"Placenta"},{"issue":"suppl","key":"10.1016\/j.ajog.2017.06.003_bib92","doi-asserted-by":"crossref","first-page":"S66","DOI":"10.1016\/j.placenta.2009.12.021","article-title":"Review: reactive oxygen and nitrogen species and functional adaptation of the placenta","volume":"31","author":"Myatt","year":"2010","journal-title":"Placenta"},{"key":"10.1016\/j.ajog.2017.06.003_bib93","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.bpobgyn.2010.10.016","article-title":"Oxidative stress","volume":"25","author":"Burton","year":"2011","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"issue":"suppl","key":"10.1016\/j.ajog.2017.06.003_bib94","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.ajog.2016.03.001","article-title":"Placental origins of adverse pregnancy outcomes: potential molecular targets: an Executive Workshop Summary of the Eunice Kennedy Shriver National Institute of Child Health and Human Development","volume":"215","author":"Ilekis","year":"2016","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2017.06.003_bib95","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/S2213-8587(15)00219-3","article-title":"Effect of metformin on maternal and fetal outcomes in obese pregnant women (EMPOWaR): a randomised, double-blind, placebo-controlled trial","volume":"3","author":"Chiswick","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.ajog.2017.06.003_bib96","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1056\/NEJMoa1509819","article-title":"Metformin versus placebo in obese pregnant women without diabetes mellitus","volume":"374","author":"Syngelaki","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ajog.2017.06.003_bib97","series-title":"Patient compliance in medical practice and clinical trials","first-page":"387","author":"Cramer","year":"1991"},{"key":"10.1016\/j.ajog.2017.06.003_bib98","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1136\/heart.88.2.203","article-title":"Effect of partial compliance on cardiovascular medication effectiveness","volume":"88","author":"Cramer","year":"2002","journal-title":"Heart"},{"key":"10.1016\/j.ajog.2017.06.003_bib99","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1046\/j.1524-4733.2003.65269.x","article-title":"Medication compliance feedback and monitoring in a clinical trial: predictors and outcomes","volume":"6","author":"Cramer","year":"2003","journal-title":"Value Health"},{"key":"10.1016\/j.ajog.2017.06.003_bib100","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/j.1524-4733.2007.00213.x","article-title":"Medication compliance and persistence: terminology and definitions","volume":"11","author":"Cramer","year":"2008","journal-title":"Value Health"},{"key":"10.1016\/j.ajog.2017.06.003_bib101","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1185\/03007995.2014.952715","article-title":"Treatment preference, adherence and outcomes in patients with cancer: literature review and development of a theoretical model","volume":"30","author":"Shingler","year":"2014","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.ajog.2017.06.003_bib102","first-page":"302","article-title":"Toxemia: new concepts in an old disease","volume":"12","author":"Romero","year":"1988","journal-title":"Semin Perinatol"},{"key":"10.1016\/j.ajog.2017.06.003_bib103","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/S0140-6736(05)17987-2","article-title":"Pre-eclampsia","volume":"365","author":"Sibai","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.ajog.2017.06.003_bib104","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1146\/annurev-pathol-121808-102149","article-title":"Pathogenesis of preeclampsia","volume":"5","author":"Young","year":"2010","journal-title":"Ann Rev Pathol"},{"key":"10.1016\/j.ajog.2017.06.003_bib105","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ajog.2010.08.009","article-title":"The \u201cGreat Obstetrical Syndromes\u201d are associated with disorders of deep placentation","volume":"204","author":"Brosens","year":"2011","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2017.06.003_bib106","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.semnephrol.2010.10.004","article-title":"Angiogenic factors and preeclampsia","volume":"31","author":"Maynard","year":"2011","journal-title":"Semin Nephrol"},{"issue":"suppl1","key":"10.1016\/j.ajog.2017.06.003_bib107","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1016\/j.revmed.2011.03.331","article-title":"Preeclampsia: a multi-stress disorder","volume":"32","author":"Redman","year":"2011","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.ajog.2017.06.003_bib108","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.preghy.2012.05.006","article-title":"Preeclampsia: no longer solely a pregnancy disease","volume":"2","author":"Tranquilli","year":"2012","journal-title":"Pregnancy Hypertens"},{"key":"10.1016\/j.ajog.2017.06.003_bib109","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1161\/HYPERTENSIONAHA.111.00250","article-title":"Redefining preeclampsia using placenta-derived biomarkers","volume":"61","author":"Staff","year":"2013","journal-title":"Hypertension"},{"issue":"suppl","key":"10.1016\/j.ajog.2017.06.003_bib110","doi-asserted-by":"crossref","first-page":"S73","DOI":"10.1016\/j.placenta.2012.11.022","article-title":"Review: preeclampsia, acute atherosis of the spiral arteries and future cardiovascular disease: two new hypotheses","volume":"34","author":"Staff","year":"2013","journal-title":"Placenta"},{"key":"10.1016\/j.ajog.2017.06.003_bib111","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/nrneph.2014.103","article-title":"Pre-eclampsia part 2: prediction, prevention and management","volume":"10","author":"Chaiworapongsa","year":"2014","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.ajog.2017.06.003_bib112","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1053\/j.semperi.2014.03.005","article-title":"Pathophysiology of ischemic placental disease","volume":"38","author":"Roberts","year":"2014","journal-title":"Semin Perinatol"},{"issue":"suppl4","key":"10.1016\/j.ajog.2017.06.003_bib113","doi-asserted-by":"crossref","first-page":"S9.e1","DOI":"10.1016\/j.ajog.2015.08.003","article-title":"Preeclampsia, biomarkers, syncytiotrophoblast stress, and placental capacity","volume":"213","author":"Redman","year":"2015","journal-title":"Am J Obstet Gynecol"},{"issue":"10","key":"10.1016\/j.ajog.2017.06.003_bib114","article-title":"Molecular mechanisms of preeclampsia. Cold Spring Harbor Perspect Med","volume":"5","author":"Hod","year":"2015"},{"key":"10.1016\/j.ajog.2017.06.003_bib115","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s11906-015-0595-4","article-title":"Preeclampsia: syndrome or disease?","volume":"17","author":"Myatt","year":"2015","journal-title":"Current Hypertens Rep"},{"issue":"suppl4","key":"10.1016\/j.ajog.2017.06.003_bib116","doi-asserted-by":"crossref","first-page":"S115","DOI":"10.1016\/j.ajog.2015.08.042","article-title":"Why is placentation abnormal in preeclampsia?","volume":"213","author":"Fisher","year":"2015","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2017.06.003_bib117","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1097\/MNH.0000000000000105","article-title":"Pathogenesis of preeclampsia","volume":"24","author":"Sircar","year":"2015","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1016\/j.ajog.2017.06.003_bib118","doi-asserted-by":"crossref","first-page":"629.e1","DOI":"10.1016\/j.ajog.2015.11.015","article-title":"Maternal plasma angiogenic index-1 (placental growth factor\/soluble vascular endothelial growth factor receptor-1) is a biomarker for the burden of placental lesions consistent with uteroplacental underperfusion: a longitudinal case-cohort study","volume":"214","author":"Korzeniewski","year":"2016","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2017.06.003_bib119","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/j.ajog.2004.03.043","article-title":"Evidence supporting a role for blockade of the vascular endothelial growth factor system in the pathophysiology of preeclampsia: Young Investigator Award","volume":"190","author":"Chaiworapongsa","year":"2004","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2017.06.003_bib120","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1080\/14767050400028816","article-title":"Plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated prior to the clinical diagnosis of pre-eclampsia","volume":"17","author":"Chaiworapongsa","year":"2005","journal-title":"J\u00a0Matern Fetal Neonatal Med"},{"key":"10.1016\/j.ajog.2017.06.003_bib121","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1080\/14767050500202493","article-title":"Evidence supporting that the excess of the sVEGFR-1 concentration in maternal plasma in preeclampsia has a uterine origin","volume":"18","author":"Bujold","year":"2005","journal-title":"J\u00a0Matern Fetal Neonatal Med"},{"key":"10.1016\/j.ajog.2017.06.003_bib122","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.ajog.2005.06.033","article-title":"An elevated maternal plasma, but not amniotic fluid, soluble fms-like tyrosine kinase-1 (sFlt-1) at the time of mid-trimester genetic amniocentesis is a risk factor for preeclampsia","volume":"193","author":"Park","year":"2005","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2017.06.003_bib123","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1080\/14767050600922677","article-title":"A\u00a0role of the anti-angiogenic factor sVEGFR-1 in\u00a0the \u2018mirror syndrome\u2019 (Ballantyne\u2019s syndrome)","volume":"19","author":"Espinoza","year":"2006","journal-title":"J\u00a0Matern Fetal Neonatal Med"},{"key":"10.1016\/j.ajog.2017.06.003_bib124","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/nm1429","article-title":"Soluble endoglin contributes to the pathogenesis of preeclampsia","volume":"12","author":"Venkatesha","year":"2006","journal-title":"Nat Med"},{"key":"10.1016\/j.ajog.2017.06.003_bib125","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1056\/NEJMoa055352","article-title":"Soluble endoglin and other circulating antiangiogenic factors in preeclampsia","volume":"355","author":"Levine","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ajog.2017.06.003_bib126","doi-asserted-by":"crossref","first-page":"326.e1","DOI":"10.1016\/j.ajog.2006.11.002","article-title":"Identification of patients at risk for early onset and\/or severe preeclampsia with the use of uterine artery Doppler velocimetry and placental growth factor","volume":"196","author":"Espinoza","year":"2007","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2017.06.003_bib127","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1080\/14767050701832833","article-title":"The maternal plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated in SGA and the magnitude of the increase relates to Doppler abnormalities in the maternal and fetal circulation","volume":"21","author":"Chaiworapongsa","year":"2008","journal-title":"J\u00a0Matern Fetal Neonatal Med"},{"key":"10.1016\/j.ajog.2017.06.003_bib128","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1080\/14767050802034545","article-title":"The change in concentrations of angiogenic and anti-angiogenic factors in maternal plasma between the first and second trimesters in risk assessment for the subsequent development of preeclampsia and small-for-gestational age","volume":"21","author":"Erez","year":"2008","journal-title":"J\u00a0Matern Fetal Neonatal Med"},{"key":"10.1016\/j.ajog.2017.06.003_bib129","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1080\/14767050701830480","volume":"21","author":"Romero","year":"2008","journal-title":"J\u00a0Matern Fetal Neonatal Med"},{"issue":"supplA","key":"10.1016\/j.ajog.2017.06.003_bib130","doi-asserted-by":"crossref","first-page":"S83","DOI":"10.1016\/j.placenta.2007.10.008","article-title":"Prediction of preeclampsia: a workshop report","volume":"29","author":"Than","year":"2008","journal-title":"Placenta"},{"key":"10.1016\/j.ajog.2017.06.003_bib131","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1080\/14767050801924118","article-title":"Whole-genome microarray and targeted analysis of angiogenesis-regulating gene expression (ENG, FLT1, VEGF, PlGF) in placentas from pre-eclamptic and small-for-gestational-age pregnancies","volume":"21","author":"Toft","year":"2008","journal-title":"J\u00a0Matern Fetal Neonatal Med"},{"key":"10.1016\/j.ajog.2017.06.003_bib132","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.3109\/14767050902994754","article-title":"A\u00a0prospective cohort study of the value of maternal plasma concentrations of angiogenic and anti-angiogenic factors in early pregnancy and midtrimester in the identification of patients destined to develop preeclampsia","volume":"22","author":"Kusanovic","year":"2009","journal-title":"J\u00a0Matern Fetal Neonatal Med"},{"key":"10.1016\/j.ajog.2017.06.003_bib133","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.3109\/14767058.2011.589932","article-title":"Maternal plasma concentrations of angiogenic\/anti-angiogenic factors are of prognostic value in patients presenting to the obstetrical triage area with the suspicion of preeclampsia","volume":"24","author":"Chaiworapongsa","year":"2011","journal-title":"J\u00a0Matern Fetal Neonatal Med"},{"key":"10.1016\/j.ajog.2017.06.003_bib134","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.3109\/14767051003681121","article-title":"An imbalance between angiogenic and anti-angiogenic factors precedes fetal death in a subset of patients: results of a longitudinal study","volume":"23","author":"Romero","year":"2010","journal-title":"J\u00a0Matern Fetal Neonatal Med"},{"key":"10.1016\/j.ajog.2017.06.003_bib135","doi-asserted-by":"crossref","first-page":"152.e1","DOI":"10.1016\/j.ajog.2010.08.049","article-title":"Circulating angiogenic and antiangiogenic factors in women with eclampsia","volume":"204","author":"Vaisbuch","year":"2011","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2017.06.003_bib136","doi-asserted-by":"crossref","first-page":"498","DOI":"10.3109\/14767058.2011.591461","article-title":"Late-onset preeclampsia is associated with an imbalance of angiogenic and anti-angiogenic factors in patients with and without placental lesions consistent with maternal underperfusion","volume":"25","author":"Soto","year":"2012","journal-title":"J\u00a0Matern Fetal Neonatal Med"},{"key":"10.1016\/j.ajog.2017.06.003_bib137","doi-asserted-by":"crossref","first-page":"287.e1","DOI":"10.1016\/j.ajog.2013.01.016","article-title":"Maternal plasma concentrations of angiogenic\/antiangiogenic factors in the third trimester of pregnancy to identify the patient at risk for stillbirth at or near term and severe late preeclampsia","volume":"208","author":"Chaiworapongsa","year":"2013","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2017.06.003_bib138","doi-asserted-by":"crossref","first-page":"132","DOI":"10.3109\/14767058.2013.806905","article-title":"Plasma concentrations of angiogenic\/anti-angiogenic factors have prognostic value in women presenting with suspected preeclampsia to the obstetrical triage area: a prospective study","volume":"27","author":"Chaiworapongsa","year":"2014","journal-title":"J\u00a0Matern Fetal Neonatal Med"},{"key":"10.1016\/j.ajog.2017.06.003_bib139","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.3109\/14767058.2014.964676","article-title":"Endocan, a putative endothelial cell marker, is elevated in preeclampsia, decreased in acute pyelonephritis, and unchanged in other obstetrical syndromes","volume":"28","author":"Adekola","year":"2015","journal-title":"J\u00a0Matern Fetal Neonatal Med"},{"key":"10.1016\/j.ajog.2017.06.003_bib140","doi-asserted-by":"crossref","first-page":"636.e1","DOI":"10.1016\/j.ajog.2014.11.035","article-title":"Maternal circulating angiogenic factors in twin and singleton pregnancies","volume":"212","author":"Faupel-Badger","year":"2015","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2017.06.003_bib141","doi-asserted-by":"crossref","first-page":"e0119547","DOI":"10.1371\/journal.pone.0119547","article-title":"Full-length human placental sFlt-1-e15a isoform induces distinct maternal phenotypes of preeclampsia in mice","volume":"10","author":"Szalai","year":"2015","journal-title":"PloS One"},{"key":"10.1016\/j.ajog.2017.06.003_bib142","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.3109\/14767058.2015.1048431","article-title":"The use of angiogenic biomarkers in maternal blood to identify which SGA fetuses will require a preterm delivery and mothers who will develop pre-eclampsia","volume":"29","author":"Chaiworapongsa","year":"2016","journal-title":"J\u00a0Matern Fetal Neonatal Med"},{"key":"10.1016\/j.ajog.2017.06.003_bib143","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1038\/nrneph.2014.102","article-title":"Pre-eclampsia part 1: current understanding of its pathophysiology","volume":"10","author":"Chaiworapongsa","year":"2014","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.ajog.2017.06.003_bib144","doi-asserted-by":"crossref","first-page":"820","DOI":"10.3109\/14767050903366119","article-title":"Serum and plasma determination of angiogenic and anti-angiogenic factors yield different results: the need for standardization in clinical practice","volume":"23","author":"Ogge","year":"2010","journal-title":"J\u00a0Matern Fetal Neonatal Med"},{"key":"10.1016\/j.ajog.2017.06.003_bib145","doi-asserted-by":"crossref","first-page":"e13263","DOI":"10.1371\/journal.pone.0013263","article-title":"Soluble fms-Like tyrosine kinase 1 (sFlt1), endoglin and placental growth factor (PlGF) in preeclampsia among high risk pregnancies","volume":"5","author":"Powers","year":"2010","journal-title":"PloS One"},{"key":"10.1016\/j.ajog.2017.06.003_bib146","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1161\/CIRCULATIONAHA.111.054361","article-title":"Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia","volume":"125","author":"Rana","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.ajog.2017.06.003_bib147","doi-asserted-by":"crossref","first-page":"89.e1","DOI":"10.1016\/j.ajog.2016.01.168","article-title":"Sequential plasma angiogenic factors levels in women with suspected preeclampsia","volume":"215","author":"Baltajian","year":"2016","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2017.06.003_bib148","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1161\/HYPERTENSIONAHA.116.06421","article-title":"Angiogenic factors in preeclampsia: from diagnosis to therapy","volume":"67","author":"Karumanchi","year":"2016","journal-title":"Hypertension"},{"key":"10.1016\/j.ajog.2017.06.003_bib149","doi-asserted-by":"crossref","first-page":"782.e1","DOI":"10.1016\/j.ajog.2016.07.056","article-title":"In vivo uteroplacental release of placental growth factor and soluble Fms-like tyrosine kinase-1 in normal and preeclamptic pregnancies","volume":"215","author":"Holme","year":"2016","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2017.06.003_bib150","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1097\/GRF.0000000000000267","article-title":"Angiogenic and antiangiogenic markers for prediction and risk classification of preeclampsia","volume":"60","author":"Malshe","year":"2017","journal-title":"Clin Obstet Gynecol"},{"key":"10.1016\/j.ajog.2017.06.003_bib151","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1056\/NEJMoa031884","article-title":"Circulating angiogenic factors and the risk of preeclampsia","volume":"350","author":"Levine","year":"2004","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.ajog.2017.06.003_bib152","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1159\/000359968","article-title":"Competing risks model in screening for preeclampsia by serum placental growth factor and soluble fms-like tyrosine kinase-1 at 30-33 weeks\u2019 gestation","volume":"35","author":"Lai","year":"2014","journal-title":"Fetal Diagn Ther"},{"key":"10.1016\/j.ajog.2017.06.003_bib153","doi-asserted-by":"crossref","first-page":"87.e1","DOI":"10.1016\/j.ajog.2016.02.016","article-title":"Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 30-34 weeks\u2019 gestation","volume":"215","author":"Tsiakkas","year":"2016","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2017.06.003_bib154","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1161\/01.HYP.0000187899.34379.b0","article-title":"Circulating angiogenic factors in the pathogenesis and prediction of preeclampsia","volume":"46","author":"Lam","year":"2005","journal-title":"Hypertension"},{"key":"10.1016\/j.ajog.2017.06.003_bib155","doi-asserted-by":"crossref","first-page":"619.e1","DOI":"10.1016\/j.ajog.2015.11.016","article-title":"Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 19-24 weeks' gestation","volume":"214","author":"Gallo","year":"2016","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2017.06.003_bib156","doi-asserted-by":"crossref","first-page":"244.e1","DOI":"10.1016\/j.ajog.2007.06.030","article-title":"Angiogenic factors for the prediction of preeclampsia in high-risk women","volume":"197","author":"Moore Simas","year":"2007","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2017.06.003_bib157","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1161\/01.HYP.0000258404.21552.a3","article-title":"Predictive value of maternal angiogenic factors in second trimester pregnancies with abnormal uterine perfusion","volume":"49","author":"Stepan","year":"2007","journal-title":"Hypertension"},{"key":"10.1016\/j.ajog.2017.06.003_bib158","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.ijgo.2008.02.016","article-title":"Angiogenic factors for the prediction of pre-eclampsia in women with abnormal midtrimester uterine artery Doppler velocimetry","volume":"102","author":"Diab","year":"2008","journal-title":"Int J Gynaecol Obstet"},{"key":"10.1016\/j.ajog.2017.06.003_bib159","doi-asserted-by":"crossref","first-page":"175.e1","DOI":"10.1016\/j.ajog.2007.08.052","article-title":"Circulatory soluble endoglin and its predictive value for preeclampsia in second-trimester pregnancies with abnormal uterine perfusion","volume":"198","author":"Stepan","year":"2008","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2017.06.003_bib160","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1161\/HYPERTENSIONAHA.111.184192","article-title":"The role of angiogenic factors in the prediction and diagnosis of preeclampsia superimposed on chronic hypertension","volume":"59","author":"Garovic","year":"2012","journal-title":"Hypertension"},{"key":"10.1016\/j.ajog.2017.06.003_bib161","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1373\/clinchem.2011.169094","article-title":"The promise of angiogenic markers for the early diagnosis and prediction of preeclampsia","volume":"58","author":"Hagmann","year":"2012","journal-title":"Clin Chem"},{"key":"10.1016\/j.ajog.2017.06.003_bib162","doi-asserted-by":"crossref","first-page":"3671","DOI":"10.2337\/dc13-0944","article-title":"The role of angiogenic and antiangiogenic factors in the second trimester in the prediction of preeclampsia in pregnant women with type 1 diabetes","volume":"36","author":"Holmes","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ajog.2017.06.003_bib163","doi-asserted-by":"crossref","first-page":"407.e1","DOI":"10.1016\/j.ajog.2012.08.010","article-title":"Longitudinal evaluation of predictive value for preeclampsia of circulating angiogenic factors through pregnancy","volume":"207","author":"McElrath","year":"2012","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2017.06.003_bib164","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa1414838","article-title":"Predictive Value of the sFlt-1:PlGF Ratio in Women with Suspected Preeclampsia","volume":"374","author":"Zeisler","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajog.2017.06.003_bib165","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1111\/1471-0528.12195","article-title":"Angiogenic factors combined with clinical risk factors to predict preterm pre-eclampsia in nulliparous women: a predictive test accuracy study","volume":"120","author":"Myers","year":"2013","journal-title":"BJOG"},{"key":"10.1016\/j.ajog.2017.06.003_bib166","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.preghy.2013.04.002","article-title":"Prediction and diagnosis of pre-eclampsia; the scientific basis","volume":"3","author":"Poston","year":"2013","journal-title":"Pregnancy Hypertens"},{"key":"10.1016\/j.ajog.2017.06.003_bib167","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1042\/CS20110097","article-title":"Angiogenic growth factors in the diagnosis and prediction of pre-eclampsia","volume":"122","author":"Verlohren","year":"2012","journal-title":"Clin Sci"},{"key":"10.1016\/j.ajog.2017.06.003_bib168","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1002\/uog.6244","article-title":"Maternal serum placental growth factor at 11\u00a0+ 0 to 13\u00a0+ 6 weeks of gestation in the prediction of pre-eclampsia","volume":"32","author":"Akolekar","year":"2008","journal-title":"Ultrasound Obstet Gynecol"},{"key":"10.1016\/j.ajog.2017.06.003_bib169","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1002\/uog.7621","article-title":"Maternal plasma soluble endoglin at 11-13 weeks\u2019 gestation in pre-eclampsia","volume":"35","author":"Foidart","year":"2010","journal-title":"Ultrasound Obstet Gynecol"},{"key":"10.1016\/j.ajog.2017.06.003_bib170","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1159\/000358302","article-title":"Added value of angiogenic factors for the prediction of early and late preeclampsia in the first trimester of pregnancy","volume":"35","author":"Crovetto","year":"2014","journal-title":"Fetal Diagn Ther"},{"key":"10.1016\/j.ajog.2017.06.003_bib171","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1159\/000362518","article-title":"Competing risks model in screening for preeclampsia by biophysical and biochemical markers at 30-33 weeks\u2019 gestation","volume":"36","author":"Garcia-Tizon Larroca","year":"2014","journal-title":"Fetal Diagn Ther"},{"key":"10.1016\/j.ajog.2017.06.003_bib172","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.3109\/14767058.2013.847415","article-title":"Angiogenic biomarkers for prediction of early preeclampsia onset in high-risk women","volume":"27","author":"Moore Simas","year":"2014","journal-title":"J\u00a0Matern Fetal Neonatal Med"},{"key":"10.1016\/j.ajog.2017.06.003_bib173","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1002\/pd.4519","article-title":"First trimester screening for early and late preeclampsia based on maternal characteristics, biophysical parameters, and angiogenic factors","volume":"35","author":"Crovetto","year":"2015","journal-title":"Prenatal Diagn"},{"key":"10.1016\/j.ajog.2017.06.003_bib174","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.preghy.2015.09.004","article-title":"Accuracy of angiogenic biomarkers at 20weeks\u2019 gestation in predicting the risk of pre-eclampsia: a WHO multicentre study","volume":"5","author":"Widmer","year":"2015","journal-title":"Pregnancy Hypertens"},{"key":"10.1016\/j.ajog.2017.06.003_bib175","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ejogrb.2016.08.036","article-title":"Italian Advisory Board: sFlt-1\/PlGF ratio and preeclampsia, state of the art and developments in diagnostic, therapeutic and clinical management","volume":"206","author":"Di Martino","year":"2016","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1016\/j.ajog.2017.06.003_bib176","doi-asserted-by":"crossref","first-page":"537","DOI":"10.3109\/14767058.2015.1012063","article-title":"Predictive value of angiogenic factors, clinical risk factors and uterine artery Doppler for pre-eclampsia and fetal growth restriction in second and third trimester pregnancies in an Ecuadorian population","volume":"29","author":"Kienast","year":"2016","journal-title":"J\u00a0Matern Fetal Neonatal Med"},{"key":"10.1016\/j.ajog.2017.06.003_bib177","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1002\/uog.15750","article-title":"Longitudinal changes in maternal serum placental growth factor and soluble fms-like tyrosine kinase-1 in women at increased risk of pre-eclampsia","volume":"47","author":"Khalil","year":"2016","journal-title":"Ultrasound Obstet Gynecol"},{"key":"10.1016\/j.ajog.2017.06.003_bib178","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1159\/000345090","article-title":"Maternal serum placental growth factor, pregnancy-associated plasma protein-a and free beta-human chorionic gonadotrophin at 30-33 weeks in the prediction of pre-eclampsia","volume":"33","author":"Lai","year":"2013","journal-title":"Fetal Diagn Ther"},{"key":"10.1016\/j.ajog.2017.06.003_bib179","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1159\/000357842","article-title":"Maternal serum placental growth factor (PlGF) isoforms 1 and 2 at 11-13 weeks\u2019 gestation in normal and pathological pregnancies","volume":"36","author":"Nucci","year":"2014","journal-title":"Fetal Diagn Ther"},{"key":"10.1016\/j.ajog.2017.06.003_bib180","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1172\/JCI17189","article-title":"Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia","volume":"111","author":"Maynard","year":"2003","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.ajog.2017.06.003_bib181","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0002-9378(16)32330-4","article-title":"Syndrome of hemolysis, elevated liver enzymes, and low platelet count: a severe consequence of hypertension in pregnancy","volume":"142","author":"Weinstein","year":"1982","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2017.06.003_bib182","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1055\/s-2007-999675","article-title":"Clinical significance of liver dysfunction in pregnancy-induced hypertension","volume":"5","author":"Romero","year":"1988","journal-title":"Am J Perinatol"},{"key":"10.1016\/j.ajog.2017.06.003_bib183","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ejogrb.2012.09.026","article-title":"Pathogenesis of the syndrome of hemolysis, elevated liver enzymes, and low platelet count (HELLP): a review","volume":"166","author":"Abildgaard","year":"2013","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1016\/j.ajog.2017.06.003_bib184","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s12253-014-9872-9","article-title":"Activation of villous trophoblastic p38 and ERK1\/2 signaling pathways in preterm preeclampsia and HELLP syndrome","volume":"21","author":"Szabo","year":"2015","journal-title":"Pathol Oncol Res"},{"key":"10.1016\/j.ajog.2017.06.003_bib185","doi-asserted-by":"crossref","first-page":"e0157584","DOI":"10.1371\/journal.pone.0157584","article-title":"Association between placental lesions, cytokines and angiogenic factors in pregnant women with preeclampsia","volume":"11","author":"Weel","year":"2016","journal-title":"PloS One"},{"key":"10.1016\/j.ajog.2017.06.003_bib186","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1097\/01.AOG.0000266983.77458.71","article-title":"Recurrence of ischemic placental disease","volume":"110","author":"Ananth","year":"2007","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ajog.2017.06.003_bib187","doi-asserted-by":"crossref","first-page":"273.e1","DOI":"10.1016\/j.ajog.2007.05.047","article-title":"Chronic hypertension and risk of placental abruption: is the association modified by ischemic placental disease?","volume":"197","author":"Ananth","year":"2007","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2017.06.003_bib188","doi-asserted-by":"crossref","first-page":"887","DOI":"10.3109\/14767050903334885","article-title":"Ischemic placental disease: maternal versus fetal clinical presentations by gestational age","volume":"23","author":"Ananth","year":"2010","journal-title":"J\u00a0Matern Fetal Neonatal Med"},{"key":"10.1016\/j.ajog.2017.06.003_bib189","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ejogrb.2011.07.025","article-title":"Ischemic placental disease: epidemiology and risk factors","volume":"159","author":"Ananth","year":"2011","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1016\/j.ajog.2017.06.003_bib190","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/j.1471-0528.1995.tb09020.x","article-title":"Interleukin-6, tumour necrosis factor and soluble tumour necrosis factor receptors in women with pre-eclampsia","volume":"102","author":"Vince","year":"1995","journal-title":"Br J Obstet Gynaecol"},{"key":"10.1016\/j.ajog.2017.06.003_bib191","first-page":"1272","article-title":"The relationships between leptin and inflammatory cytokines in women with pre-eclampsia","volume":"108","author":"Bartha","year":"2001","journal-title":"BJOG"},{"key":"10.1016\/j.ajog.2017.06.003_bib192","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1034\/j.1600-0897.2002.01087.x","article-title":"High serum interleukin-8 levels in afro-caribbean women with pre-eclampsia: relations with tumor necrosis factor-alpha, duffy negative phenotype and von Willebrand factor","volume":"48","author":"Velzing-Aarts","year":"2002","journal-title":"Am j reprod immunol"},{"key":"10.1016\/j.ajog.2017.06.003_bib193","first-page":"713","article-title":"Soluble tumor necrosis factor receptor II and soluble cell adhesion molecule 1 as markers of tumor necrosis factor-alpha release in preeclampsia","volume":"81","author":"Visser","year":"2002","journal-title":"Acta Obstet Gynecol Scand"},{"key":"10.1016\/j.ajog.2017.06.003_bib194","doi-asserted-by":"crossref","first-page":"880","DOI":"10.3109\/14767051003774942","article-title":"Maternal and umbilical serum levels of interleukin-6, interleukin-8, and tumor necrosis factor-alpha in normal pregnancies and in pregnancies complicated by preeclampsia","volume":"23","author":"Tosun","year":"2010","journal-title":"J\u00a0Matern Fetal Neonatal Med"},{"key":"10.1016\/j.ajog.2017.06.003_bib195","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/1471-2172-11-59","article-title":"Circulating cytokines, chemokines and adhesion molecules in normal pregnancy and preeclampsia determined by multiplex suspension array","volume":"11","author":"Szarka","year":"2010","journal-title":"BMC Immunol"},{"key":"10.1016\/j.ajog.2017.06.003_bib196","doi-asserted-by":"crossref","first-page":"145","DOI":"10.3109\/00016348909009902","article-title":"Pre-eclampsia: a mitochondrial disease?","volume":"68","author":"Torbergsen","year":"1989","journal-title":"Acta Obstet Gynecol Scand"},{"key":"10.1016\/j.ajog.2017.06.003_bib197","doi-asserted-by":"crossref","first-page":"110","DOI":"10.2174\/1573402111666150529130703","article-title":"The involvement of uric acid in the pathogenesis of preeclampsia","volume":"11","author":"Masoura","year":"2015","journal-title":"Curr Hypertens Rev"},{"key":"10.1016\/j.ajog.2017.06.003_bib198","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/0002-9378(90)91102-I","article-title":"Ultrastructural aspects of preeclampsia: II, mitochondrial changes","volume":"163","author":"Shanklin","year":"1990","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2017.06.003_bib199","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/0002-9378(90)90837-W","article-title":"Mitochondrial myopathy and preeclampsia associated with pregnancy","volume":"162","author":"Berkowitz","year":"1990","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2017.06.003_bib200","doi-asserted-by":"crossref","first-page":"e64351","DOI":"10.1371\/journal.pone.0064351","article-title":"Comparative proteomics analysis suggests that placental mitochondria are involved in the development of pre-eclampsia","volume":"8","author":"Shi","year":"2013","journal-title":"PloS One"},{"key":"10.1016\/j.ajog.2017.06.003_bib201","first-page":"237","article-title":"A\u00a0case-control study of maternal blood mitochondrial DNA copy number and preeclampsia risk","volume":"3","author":"Qiu","year":"2012","journal-title":"Int J Mol Epidemiol Genet"},{"key":"10.1016\/j.ajog.2017.06.003_bib202","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jri.2007.03.006","article-title":"Preeclampsia: a view through the danger model","volume":"76","author":"Bonney","year":"2007","journal-title":"J\u00a0Reprod Immunol"},{"key":"10.1016\/j.ajog.2017.06.003_bib203","doi-asserted-by":"crossref","first-page":"E404","DOI":"10.1152\/ajpendo.00426.2013","article-title":"Placental mitochondrial content and function in intrauterine growth restriction and preeclampsia","volume":"306","author":"Mando","year":"2014","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.ajog.2017.06.003_bib204","doi-asserted-by":"crossref","first-page":"661.e1","DOI":"10.1016\/j.ajog.2008.12.045","article-title":"Differential expression profile of microRNAs in human placentas from preeclamptic pregnancies vs normal pregnancies","volume":"200","author":"Zhu","year":"2009","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2017.06.003_bib205","doi-asserted-by":"crossref","first-page":"261.e1","DOI":"10.1016\/j.ajog.2007.01.008","article-title":"Distinct subsets of microRNAs are expressed differentially in the human placentas of patients with preeclampsia","volume":"196","author":"Pineles","year":"2007","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2017.06.003_bib206","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.ajpath.2011.04.035","article-title":"MiR-210 targets iron-sulfur cluster scaffold homologue in human trophoblast cell lines: siderosis of interstitial trophoblasts as a novel pathology of preterm preeclampsia and small-for-gestational-age pregnancies","volume":"179","author":"Lee","year":"2011","journal-title":"Am J Pathol"},{"key":"10.1016\/j.ajog.2017.06.003_bib207","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.placenta.2012.07.002","article-title":"MIR-210 modulates mitochondrial respiration in placenta with preeclampsia","volume":"33","author":"Muralimanoharan","year":"2012","journal-title":"Placenta"},{"key":"10.1016\/j.ajog.2017.06.003_bib208","doi-asserted-by":"crossref","first-page":"32410","DOI":"10.1038\/srep32410","article-title":"Mitochondrial role in adaptive response to stress conditions in preeclampsia","volume":"6","author":"Vishnyakova","year":"2016","journal-title":"Sci Rep"},{"issue":"suppl1","key":"10.1016\/j.ajog.2017.06.003_bib209","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.placenta.2015.11.014","article-title":"IFPA meeting 2015 workshop report I: placental mitochondrial function, transport systems and epigenetics","volume":"48","author":"Bianco-Miotto","year":"2016","journal-title":"Placenta"},{"key":"10.1016\/j.ajog.2017.06.003_bib210","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1042\/bj3480607","article-title":"Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain","volume":"348","author":"Owen","year":"2000","journal-title":"Biochem J"},{"key":"10.1016\/j.ajog.2017.06.003_bib211","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1111\/jdi.12328","article-title":"New mechanisms of metformin action: Focusing on mitochondria and the gut","volume":"6","author":"Hur","year":"2015","journal-title":"J\u00a0Diabetes Investig"},{"key":"10.1016\/j.ajog.2017.06.003_bib212","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/nature13270","article-title":"Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase","volume":"510","author":"Madiraju","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.ajog.2017.06.003_bib213","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ccr.2004.11.022","article-title":"Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase","volume":"7","author":"Selak","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ajog.2017.06.003_bib214","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1038\/nature06951","article-title":"Deficiency in catechol-O-methyltransferase and 2-methoxyoestradiol is associated with pre-eclampsia","volume":"453","author":"Kanasaki","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.ajog.2017.06.003_bib215","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1095\/biolreprod.112.102723","article-title":"The role of hypoxia and hypoxia-inducible factor-1alpha in preeclampsia pathogenesis","volume":"87","author":"Tal","year":"2012","journal-title":"Biol Reprod"},{"key":"10.1016\/j.ajog.2017.06.003_bib216","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1172\/JCI13505","article-title":"Role of AMP-activated protein kinase in mechanism of metformin action","volume":"108","author":"Zhou","year":"2001","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.ajog.2017.06.003_bib217","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1038\/nature11808","article-title":"Biguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMP","volume":"494","author":"Miller","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.ajog.2017.06.003_bib218","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s10863-006-9003-8","article-title":"The ROS production induced by a reverse-electron flux at respiratory-chain complex 1 is hampered by metformin","volume":"38","author":"Batandier","year":"2006","journal-title":"J\u00a0Bioenerg Biomembr"},{"key":"10.1016\/j.ajog.2017.06.003_bib219","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1007\/s11064-014-1496-7","article-title":"Intracerebroventricular metformin decreases body weight but has pro-oxidant effects and decreases survival","volume":"40","author":"Portela","year":"2015","journal-title":"Neurochem Res"},{"key":"10.1016\/j.ajog.2017.06.003_bib220","doi-asserted-by":"crossref","first-page":"357","DOI":"10.18632\/aging.100040","article-title":"Growth and aging: a common molecular mechanism","volume":"1","author":"Blagosklonny","year":"2009","journal-title":"Aging"},{"key":"10.1016\/j.ajog.2017.06.003_bib221","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.cell.2015.02.041","article-title":"Nutrient-sensing mechanisms across evolution","volume":"161","author":"Chantranupong","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.ajog.2017.06.003_bib222","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1373\/clinchem.2004.032482","article-title":"Endocrine regulation of energy metabolism: review of pathobiochemical and clinical chemical aspects of leptin, ghrelin, adiponectin, and resistin","volume":"50","author":"Meier","year":"2004","journal-title":"Clin Chem"},{"key":"10.1016\/j.ajog.2017.06.003_bib223","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1042\/CS20160006","article-title":"Energy balance, body composition, sedentariness and appetite regulation: pathways to obesity","volume":"130","author":"Hopkins","year":"2016","journal-title":"Clin Sci"},{"key":"10.1016\/j.ajog.2017.06.003_bib224","doi-asserted-by":"crossref","first-page":"E994","DOI":"10.1152\/ajpendo.00121.2016","article-title":"Hypothalamic roles of mTOR complex I: integration of nutrient and hormone signals to regulate energy homeostasis","volume":"310","author":"Hu","year":"2016","journal-title":"Am J Physiol Endocrinol Metabol"},{"key":"10.1016\/j.ajog.2017.06.003_bib225","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1097\/GRF.0b013e3182993a2e","article-title":"Role of placental nutrient sensing in developmental programming","volume":"56","author":"Jansson","year":"2013","journal-title":"Clin Obstet Gynecol"},{"key":"10.1016\/j.ajog.2017.06.003_bib226","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1042\/BST0370295","article-title":"Placental mTOR links maternal nutrient availability to fetal growth","volume":"37","author":"Roos","year":"2009","journal-title":"Biochem Soc Trans"},{"key":"10.1016\/j.ajog.2017.06.003_bib227","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1113\/jphysiol.2012.238014","article-title":"Mammalian target of rapamycin signalling modulates amino acid uptake by regulating transporter cell surface abundance in primary human trophoblast cells","volume":"591","author":"Rosario","year":"2013","journal-title":"J\u00a0Physiol"},{"key":"10.1016\/j.ajog.2017.06.003_bib228","doi-asserted-by":"crossref","first-page":"721","DOI":"10.7164\/antibiotics.28.721","article-title":"Rapamycin (AY-22,989), a new antifungal antibiotic: I, taxonomy of the producing streptomycete and isolation of the active principle","volume":"28","author":"Vezina","year":"1975","journal-title":"J\u00a0Antibiot"},{"key":"10.1016\/j.ajog.2017.06.003_bib229","doi-asserted-by":"crossref","first-page":"a025924","DOI":"10.1101\/cshperspect.a025924","article-title":"Inhibition of the mechanistic target of rapamycin (mTOR)-rapamycin and beyond","volume":"6","author":"Lamming","year":"2016","journal-title":"Cold Spring Harbor Perspect Med"},{"key":"10.1016\/j.ajog.2017.06.003_bib230","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/nrm3025","article-title":"mTOR: from growth signal integration to cancer, diabetes and ageing","volume":"12","author":"Zoncu","year":"2011","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.ajog.2017.06.003_bib231","doi-asserted-by":"crossref","first-page":"18073","DOI":"10.1073\/pnas.1108180108","article-title":"Heightened uterine mammalian target of rapamycin complex 1 (mTORC1) signaling provokes preterm birth in mice","volume":"108","author":"Hirota","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ajog.2017.06.003_bib232","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/nrm3757","article-title":"Making new contacts: the mTOR network in metabolism and signalling crosstalk","volume":"15","author":"Shimobayashi","year":"2014","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.ajog.2017.06.003_bib233","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1172\/JCI73939","article-title":"MTOR: a pharmacologic target for autophagy regulation","volume":"125","author":"Kim","year":"2015","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.ajog.2017.06.003_bib234","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.1172\/JCI87715","article-title":"P53 coordinates decidual sestrin 2\/AMPK\/mTORC1 signaling to govern parturition timing","volume":"126","author":"Deng","year":"2016","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.ajog.2017.06.003_bib235","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.cmet.2016.05.009","article-title":"The mechanistic target of rapamycin: the grand conducTOR of metabolism and aging","volume":"23","author":"Kennedy","year":"2016","journal-title":"Cell Metab"},{"key":"10.1016\/j.ajog.2017.06.003_bib236","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.12688\/f1000research.9207.1","article-title":"MTOR inhibitors in cancer therapy","volume":"5","author":"Xie","year":"2016","journal-title":"F1000Res"},{"key":"10.1016\/j.ajog.2017.06.003_bib237","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1126\/science.aaa3870","article-title":"Architecture of human mTOR complex 1","volume":"351","author":"Aylett","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.ajog.2017.06.003_bib238","first-page":"263","article-title":"MTOR signaling from cellular senescence to organismal aging","volume":"5","author":"Xu","year":"2014","journal-title":"Aging Dis"},{"key":"10.1016\/j.ajog.2017.06.003_bib239","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/brv.12103","article-title":"The role of mitochondria in mTOR-regulated longevity","volume":"90","author":"Wei","year":"2015","journal-title":"Biol Rev Camb Philos Soc"},{"key":"10.1016\/j.ajog.2017.06.003_bib240","first-page":"179827","article-title":"Regulation of nutrient transport across the placenta","volume":"2012","author":"Lager","year":"2012","journal-title":"J\u00a0Pregnancy"},{"key":"10.1016\/j.ajog.2017.06.003_bib241","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1677\/JOE-10-0027","article-title":"Role of extracellular signal-regulated kinase and AKT cascades in regulating hypoxia-induced angiogenic factors produced by a trophoblast-derived cell line","volume":"206","author":"Fujita","year":"2010","journal-title":"J\u00a0Endocrinol"},{"key":"10.1016\/j.ajog.2017.06.003_bib242","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.ajog.2006.05.047","article-title":"Transfer of metformin across the dually perfused human placental lobule","volume":"195","author":"Nanovskaya","year":"2006","journal-title":"Am J Obstet Gynecol"},{"issue":"7420","key":"10.1016\/j.ajog.2017.06.003_bib243","first-page":"880","article-title":"Metformin crosses the placenta: a modulator for fetal insulin\u00a0resistance?","volume":"327","author":"Charles","year":"2004","journal-title":"Br Med J"},{"key":"10.1016\/j.ajog.2017.06.003_bib244","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/j.fertnstert.2004.11.051","article-title":"Placental passage of metformin in women with polycystic ovary syndrome","volume":"83","author":"Vanky","year":"2005","journal-title":"Fertil Steril"},{"key":"10.1016\/j.ajog.2017.06.003_bib245","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1093\/humupd\/dmu022","article-title":"First-trimester exposure to metformin and risk of birth defects: a systematic review and meta-analysis","volume":"20","author":"Cassina","year":"2014","journal-title":"Hum Reprod Update"},{"key":"10.1016\/j.ajog.2017.06.003_bib246","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.fertnstert.2006.02.098","article-title":"Pregnancy outcome after first-trimester exposure to metformin: a meta-analysis","volume":"86","author":"Gilbert","year":"2006","journal-title":"Fertil steril"},{"key":"10.1016\/j.ajog.2017.06.003_bib247","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1111\/dom.12893","article-title":"The emerging role of metformin in gestational diabetes mellitus","volume":"19","author":"Gray","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.ajog.2017.06.003_bib248","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1056\/NEJMct0707092","article-title":"Metformin for the treatment of the polycystic ovary syndrome","volume":"358","author":"Nestler","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ajog.2017.06.003_bib249","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.bpobgyn.2010.10.018","article-title":"Oral hypoglycaemic agents during pregnancy: the evidence for effectiveness and safety","volume":"25","author":"Nicholson","year":"2011","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"10.1016\/j.ajog.2017.06.003_bib250","doi-asserted-by":"crossref","first-page":"F488","DOI":"10.1136\/archdischild-2015-309602","article-title":"Neurodevelopmental outcome at 2 years in offspring of women randomised to metformin or insulin treatment for gestational diabetes","volume":"101","author":"Wouldes","year":"2016","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"key":"10.1016\/j.ajog.2017.06.003_bib251","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.2337\/dc11-0660","article-title":"Metformin in gestational diabetes: the offspring follow-up (MiG TOFU): body composition at 2 years of age","volume":"34","author":"Rowan","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ajog.2017.06.003_bib252","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1016\/j.metabol.2013.06.006","article-title":"Efficacy and safety of metformin during pregnancy in women with gestational diabetes mellitus or polycystic ovary syndrome: a systematic review","volume":"62","author":"Lautatzis","year":"2013","journal-title":"Metabolism"},{"key":"10.1016\/j.ajog.2017.06.003_bib253","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1136\/bmj.38415.708634.F7","article-title":"Metformin and reduced risk of cancer in diabetic patients","volume":"330","author":"Evans","year":"2005","journal-title":"BMJ"},{"key":"10.1016\/j.ajog.2017.06.003_bib254","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.2337\/dc08-2175","article-title":"New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes","volume":"32","author":"Libby","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ajog.2017.06.003_bib255","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1158\/1940-6207.CAPR-13-0424","article-title":"Metformin and cancer risk and mortality: a systematic review and meta-analysis taking into account biases and confounders","volume":"7","author":"Gandini","year":"2014","journal-title":"Cancer Prev Res"},{"key":"10.1016\/j.ajog.2017.06.003_bib256","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1593\/tlo.13556","article-title":"Antidiabetic drug metformin prevents progression of pancreatic cancer by targeting in part cancer stem cells and mTOR signaling","volume":"6","author":"Mohammed","year":"2013","journal-title":"Transl Oncol"},{"key":"10.1016\/j.ajog.2017.06.003_bib257","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.exger.2005.07.007","article-title":"Effect of metformin on life span and on the development of spontaneous mammary tumors in HER-2\/neu transgenic mice","volume":"40","author":"Anisimov","year":"2005","journal-title":"Exp gerontol"},{"key":"10.1016\/j.ajog.2017.06.003_bib258","first-page":"60","article-title":"Do metformin a real anticarcinogen? A critical reappraisal of experimental data","volume":"2","author":"Anisimov","year":"2014","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.ajog.2017.06.003_bib259","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.jsps.2012.05.012","article-title":"Preventive effect of Metformin against N-nitrosodiethylamine-initiated hepatocellular carcinoma in rats","volume":"20","author":"Afzal","year":"2012","journal-title":"Saudi Pharm J"},{"key":"10.1016\/j.ajog.2017.06.003_bib260","doi-asserted-by":"crossref","first-page":"148","DOI":"10.18632\/aging.100273","article-title":"If started early in life, metformin treatment increases life span and postpones tumors in female SHR mice","volume":"3","author":"Anisimov","year":"2011","journal-title":"Aging"},{"key":"10.1016\/j.ajog.2017.06.003_bib261","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1042\/BJ20080557","article-title":"Important role of the LKB1-AMPK pathway in suppressing tumorigenesis in PTEN-deficient mice","volume":"412","author":"Huang","year":"2008","journal-title":"Biochem J"},{"key":"10.1016\/j.ajog.2017.06.003_bib262","doi-asserted-by":"crossref","first-page":"E987","DOI":"10.1152\/ajpendo.00133.2013","article-title":"Metformin prevents liver tumorigenesis induced by high-fat diet in C57Bl\/6 mice","volume":"305","author":"Tajima","year":"2013","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.ajog.2017.06.003_bib263","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1111\/j.1349-7006.2008.00933.x","article-title":"Metformin suppresses intestinal polyp growth in ApcMin\/+ mice","volume":"99","author":"Tomimoto","year":"2008","journal-title":"Cancer Sci"},{"key":"10.1016\/j.ajog.2017.06.003_bib264","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.drup.2011.04.003","article-title":"Repositioning chloroquine and metformin to eliminate cancer stem cell traits in pre-malignant lesions","volume":"14","author":"Vazquez-Martin","year":"2011","journal-title":"Drug Resist Updat"},{"key":"10.1016\/j.ajog.2017.06.003_bib265","doi-asserted-by":"crossref","first-page":"4461","DOI":"10.4161\/cc.9.22.14048","article-title":"Metformin against TGFbeta-induced epithelial-to-mesenchymal transition (EMT): from cancer stem cells to aging-associated fibrosis","volume":"9","author":"Cufi","year":"2010","journal-title":"Cell cycle"},{"key":"10.1016\/j.ajog.2017.06.003_bib266","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nrc2676","article-title":"The LKB1-AMPK pathway: metabolism and growth control in tumour suppression","volume":"9","author":"Shackelford","year":"2009","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ajog.2017.06.003_bib267","doi-asserted-by":"crossref","first-page":"4262","DOI":"10.1182\/blood-2010-02-269837","article-title":"The LKB1\/AMPK signaling pathway has tumor suppressor activity in acute myeloid leukemia through the repression of mTOR-dependent oncogenic mRNA translation","volume":"116","author":"Green","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.ajog.2017.06.003_bib268","doi-asserted-by":"crossref","first-page":"10269","DOI":"10.1158\/0008-5472.CAN-06-1500","article-title":"Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells","volume":"66","author":"Zakikhani","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.ajog.2017.06.003_bib269","first-page":"317","article-title":"Managing lipid metabolism in proliferating cells: new perspective for metformin usage in cancer therapy","volume":"1845","author":"Lettieri Barbato","year":"2014","journal-title":"Biochimica et biophysica acta"},{"key":"10.1016\/j.ajog.2017.06.003_bib270","doi-asserted-by":"crossref","first-page":"3297","DOI":"10.1200\/JCO.2009.19.6410","article-title":"Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer","volume":"27","author":"Jiralerspong","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ajog.2017.06.003_bib271","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.phrs.2016.10.006","article-title":"Metformin: an anti-diabetic drug to\u00a0fight cancer","volume":"113","author":"Daugan","year":"2016","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.ajog.2017.06.003_bib272","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.pharep.2016.04.021","article-title":"Molecular targets of metformin antitumor action","volume":"68","author":"Sosnicki","year":"2016","journal-title":"Pharmacol Rep"},{"key":"10.1016\/j.ajog.2017.06.003_bib273","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/ng1056","article-title":"A\u00a0systematic RNAi screen identifies a critical role for mitochondria in C elegans longevity","volume":"33","author":"Lee","year":"2003","journal-title":"Nature Genet"},{"key":"10.1016\/j.ajog.2017.06.003_bib274","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1126\/science.1077780","article-title":"Rates of behavior and aging specified by mitochondrial function during development","volume":"298","author":"Dillin","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.ajog.2017.06.003_bib275","doi-asserted-by":"crossref","first-page":"e47699","DOI":"10.1371\/journal.pone.0047699","article-title":"Activation of AMPK by the putative dietary restriction mimetic metformin is insufficient to extend lifespan in Drosophila","volume":"7","author":"Slack","year":"2012","journal-title":"PloS One"},{"key":"10.1016\/j.ajog.2017.06.003_bib276","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.cell.2016.07.031","article-title":"Metabolic control of longevity","volume":"166","author":"Lopez-Otin","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.ajog.2017.06.003_bib277","doi-asserted-by":"crossref","first-page":"a025932","DOI":"10.1101\/cshperspect.a025932","article-title":"Metformin: a hopeful promise in aging research","volume":"6","author":"Novelle","year":"2016","journal-title":"Cold Spring Harbor Perspect Med"},{"key":"10.1016\/j.ajog.2017.06.003_bib278","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/j.cell.2016.11.055","article-title":"An ancient, unified mechanism for metformin growth inhibition in C elegans and cancer","volume":"167","author":"Wu","year":"2016","journal-title":"Cell"}],"container-title":["American Journal of Obstetrics and Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002937817307391?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002937817307391?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T11:14:47Z","timestamp":1757589287000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002937817307391"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":278,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["S0002937817307391"],"URL":"https:\/\/doi.org\/10.1016\/j.ajog.2017.06.003","relation":{},"ISSN":["0002-9378"],"issn-type":[{"value":"0002-9378","type":"print"}],"subject":[],"published":{"date-parts":[[2017,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Metformin, the aspirin of the 21st century: its\u00a0role in gestational diabetes mellitus, prevention of preeclampsia and cancer, and\u00a0the promotion of longevity","name":"articletitle","label":"Article Title"},{"value":"American Journal of Obstetrics and Gynecology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajog.2017.06.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}